Publicacións (18) Publicacións de Juan Cruz De La Cámara Gómez

2023

  1. Clinicopathological Profiles Associated with Discordant RAS Mutational Status between Liquid and Tissue Biopsies in a Real-World Cohort of Metastatic Colorectal Cancer

    Cancers, Vol. 15, Núm. 14

2022

  1. Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen

    PLoS ONE, Vol. 17, Núm. 6 June

  2. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting

    Scientific Reports, Vol. 12, Núm. 1

  3. Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer

    Clinical and Translational Oncology, Vol. 24, Núm. 6, pp. 1209-1214

2021

  1. Do clinical trials meet current care needs? Views of digestive oncology specialists in galicia (spain) using the delphi method

    Healthcare (Switzerland), Vol. 9, Núm. 6

  2. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain

    BMC Cancer, Vol. 21, Núm. 1

  3. Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 351-359

  2. First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study

    Journal of Geriatric Oncology, Vol. 11, Núm. 8, pp. 1263-1267

2019

  1. Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen

    Annals of Oncology, Vol. 30, pp. iv42-iv43

  2. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers

    Cancer Medicine, Vol. 8, Núm. 3, pp. 882-889

  3. Is there any affordable and reliable score in local gastric cancer?

    Annals of Oncology, Vol. 30, pp. iv60

  4. Predictive model of breast cancer metastasis in axillary non-sentinel lymph nodes. Emergent variables. The MOTTO study, part I

    Revista de Senologia y Patologia Mamaria, Vol. 32, Núm. 4, pp. 127-132

2018

  1. Differences in outcome according to chemotherapy backbone and maintenance treatment in HER2 positive metastatic gastric cancer (GC) or gastroesophageal junction (GEJ)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii225

2017

  1. Prognostic and predictive markers of response to treatment in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine/nab-paclitaxel: Results of a retrospective analysis

    Journal of Cancer Research and Therapeutics, Vol. 13, Núm. 2, pp. 240-245

2009

  1. Metástasis cutáneas zosteriformes de mesotelioma pleural maligno

    Revista Clinica Espanola

2008

  1. Erupción por doxorubicina liposomal pegilada: Dos nuevos casos

    Piel

2005

  1. Impact of surgery and chemotherapy on von Willebrand factor and vascular endothelial growth factor levels in colorectal cancer

    Clinical and Translational Oncology, Vol. 7, Núm. 4, pp. 150-155